Solid Biosciences (NASDAQ: SLDB)
Solid Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Solid Biosciences Company Info
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
News & Analysis
Why Shares of Solid Biosciences Are Jumping Today
Shareholders are expecting to finally get good news.
Why Solid Biosciences Stock Is Crashing Today
Investors appear to be skeptical about the biotech's latest clinical update.
Why Solid Biosciences Stock Is Sinking Today
Blame it on Sarepta.
Here's Why Solid Biosciences Fell as Much as 16.3% Today
The company announced plans to slash its head count and go all in on a single gene therapy. Is that wise or stubborn?
Here's Why Solid Biosciences Stock Got Hammered Today
Early data for its side-effect-ridden gene therapy SGT-001 doesn't look very promising.
3 Biotech Stocks With Big Incoming Catalysts
Investors expect stock-moving news from all of these drugmakers before the end of 2019.
Here's Why Solid Biosciences Collapsed Today
A clinical trial evaluating the company's lead drug candidate was placed on a clinical hold -- for the third time.
Here's Why Solid Biosciences Is Soaring Today
The clinical-stage biopharma announced changes to its lead pipeline program. Will it be enough?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.